Phase 2 trial participants lost an average of ~24% of their body weight over 48 weeks, compared to roughly 1517% with semaglutide and 2022% with tirzepatide
Conflict of interest DK has received research support from Sanofi, Tanabe Pharma, Terumo, Behringer Ingelheim, Kyowa Kirin, Sumitomo Dainippon Pharma, Ono Pharmaceutical and Takeda Pharmaceutical as well as speaker honoraria from Novo Nordisk Pharma, Sanofi, and Takeda Pharmaceutical
Patients should provide a complete medication list, including all prescription medications, over-the-counter drugs, supplements, and herbal products
Diabetes (2012) 61(7):16919
Growth hormone-releasing peptides (GHRPs) and GHRH analogs like CJC1295 are prohibited at all times under S2 class substances. World Anti-Doping Agency (WADA) Athletes in sanctioned sports should avoid use unless under physician supervision and within TUE (Therapeutic Use Exemption) protocol guidelines